Study Characteristic | TOF-MRA | CE-MRA | ||||||
Sensitivity (95% CI) | Specificity (95% CI) | Positive LR (95% CI) | Negative LR (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | Positive LR (95% CI) | Negative LR (95% CI) | |
2D DSA | 0.85 (0.82 to 0.89) | 0.92 (0.89 to 0.94) | 9.04 (5.24 to 15.59) | 0.18 (0.11 to 0.29) | 0.86 (0.79 to 0.91) | 0.94 (0.91 to 0.96) | 11.74 (5.38 to 25.59) | 0.22 (0.11 to 0.43) |
3D DSA | 0.88 (0.84 to 0.92) | 0.94 (0.91 to 0.96) | 9.51 (4.07 to 22.19) | 0.16 (0.09 to 0.30) | 0.80 (0.72 to 0.86) | 0.88 (0.78 to 0.94) | 4.17 (1.74 to 10.00) | 0.20 (0.08 to 0.50) |
1.5T MRA | 0.87 (0.83 to 0.90) | 0.93 (0.91 to 0.95) | 11.21 (6.27 to 20.06) | 0.17 (0.10 to 0.29) | 0.91 (0.86 to 0.95) | 0.94 (0.90 to 0.96) | 10.33 (5.21 to 20.47) | 0.14 (0.07 to 0.27) |
3T MRA | 0.86 (0.82 to 0.90) | 0.92 (0.88 to 0.94) | 7.16 (3.42 to 14.98) | 0.19 (0.11 to 0.32) | 0.73 (0.64 to 0.81) | 0.92 (0.86 to 0.96) | 5.75 (2.43 to 13.58) | 0.34 (0.20 to 0.60) |
GRADE 1–2 | 0.95 (0.89 to 0.98) | 0.88 (0.80 to 0.93) | 13.58 (1.60 to 115.39) | 0.09 (0.04 to 0.17) | ||||
GRADE 3–4 | 0.88 (0.85 to 0.90) | 0.95 (0.94 to 0.96) | 10.18 (6.06 to 17.10) | 0.18 (0.12 to 0.27) | 0.88 (0.84 to 0.91) | 0.96 (0.94 to 0.97) | 9.85 (4.26 to 22.82) | 0.17 (0.09 to 0.34) |
Prospective | 0.84 (0.81 to 0.87) | 0.92 (0.9 to 0.94) | 7.39 (4.43 to 12.31) | 0.21 (0.15 to 0.32) | 0.82 (0.76 to 0.87) | 0.92 (0.88 to 0.95) | 6.81 (3.54 to 13.12) | 0.24 (0.14 to 0.41) |
Retrospective | 0.93 (0.90 to 0.95) | 0.97 (0.96 to 0.98) | 16.84 (8.22 to 34.49) | 0.11 (0.05 to 0.22) | 0.94 (0.90 to 0.96) | 0.98 (0.97 to 0.99) | 23.10 (5.01 to 106.56) | 0.09 (0.02 to 0.40) |
CE, constrast-enhanced; GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; MRA, magnetic resonance angiography; TOF, time-of-flight.